This resolution matters because it moves precision medicine out of the narrow space of scientific ambition and places it where it now belongs: at the centre of health-system reform, equity, diagnostics, data governance and access.
The resolution, “Precision medicine: a path towards targeted, personalized and equitable care”, recognises what patients, clinicians and policymakers already know. Genomics, molecular diagnostics, digital health, artificial intelligence, real-world data and advanced therapies are no longer distant possibilities. They are already changing prevention, diagnosis and treatment.
But the resolution also delivers a sharper message: innovation alone will not fix healthcare.
If health systems are not ready, precision medicine could become another divider between those who can access modern care and those still waiting for basic diagnostics. That is the real policy challenge. Not whether precision medicine works, but whether countries can make it work fairly.
The science is moving. Health systems are not moving fast enough.
Precision medicine uses clinical, molecular, genomic and other health-related data to guide decisions on prevention, diagnosis and treatment. In cancer, this can mean biomarker testing to identify the right targeted therapy. In rare diseases, it can shorten years of uncertainty through genomic diagnosis. In pharmacogenomics, it can help avoid harmful or ineffective prescribing. In prevention, it can support earlier and more targeted intervention.
The promise is clear: better decisions, fewer wasted treatments, more efficient use of resources and care that is better matched to the person in front of the clinician.
But the reality is less comfortable.
Across many health systems, access to the foundations of precision medicine remains patchy. Laboratory capacity is uneven. Molecular diagnostics are not always reimbursed. Data systems often do not connect. Clinicians may lack support to interpret genomic information. Patients may hear about innovation long before they can actually benefit from it.
This is where the WHA resolution becomes politically important. It recognises that precision medicine is not just a technology agenda. It is an implementation agenda.
And implementation is where many systems are still failing.
Equity cannot be added later
One of the strongest parts of the resolution is its focus on equity. This is not decorative language. It goes to the core of the issue.
Precision medicine depends on data. If the data mostly comes from high-income countries and narrow population groups, then the tools built on that data will not serve everyone equally. If diagnostic infrastructure exists only in major academic centres, then rural patients, poorer patients and patients in under-resourced systems will be left behind. If genomic testing is available but not reimbursed, access will depend on ability to pay.
That is not personalised medicine. That is personalised inequality.
The resolution acknowledges that many populations remain underrepresented in the research and data that underpin precision medicine, including women, children, older adults, developing countries and historically underrepresented regions. It also recognises that global capacity remains uneven, with gaps in laboratory infrastructure, genomic and clinical datasets, skilled professionals and governance mechanisms.
This is the right warning at the right time.
The next phase of precision medicine cannot be built only around innovation pipelines, elite hospitals and commercial markets. It needs public-interest governance. It needs affordability. It needs inclusive research. It needs trust. And it needs countries to plan for access from the beginning, not after the technology has already arrived.
The new agenda is infrastructure, governance and money
The resolution calls on Member States to strengthen the national foundations needed to make precision medicine safe, ethical and equitable.
That means national policies. It means laboratory and diagnostic capacity. It means genomic databases, digital health platforms, AI readiness, trained professionals, regulatory frameworks and data governance. It also means sustainable financing.
This last point is critical.
Precision medicine will not scale if countries treat it as a series of isolated pilot projects. It will not scale if biomarker testing is disconnected from treatment access. It will not scale if reimbursement systems assess medicines but ignore the diagnostics needed to use them properly. It will not scale if data is collected but cannot be shared safely, securely or responsibly.
For policymakers, the message is practical: precision medicine needs a delivery model.
That delivery model must connect diagnostics, clinical pathways, data infrastructure, health technology assessment, reimbursement, workforce training and patient engagement. Without that connection, the system breaks. Patients get tested too late, not tested at all, or tested without any realistic route to treatment.
That is where policy must now catch up with science.
Why this matters for cancer care
Although the resolution applies across disease areas, cancer is one of the clearest examples of why it matters.
Precision oncology has changed the way cancer is diagnosed and treated. Biomarker testing, molecular tumour profiling, targeted therapies and immunotherapy selection have become central to modern cancer care. But access remains deeply uneven.
In too many settings, patients still face delays in pathology, limited molecular testing, unclear reimbursement, weak referral pathways and fragmented decision-making. In some countries, the therapy may be approved but the test is not available. In others, testing exists but only for patients treated in major centres. Sometimes the diagnostic result arrives too late to guide treatment.
This is the gap between innovation and real-world care.
The WHA resolution gives policymakers a stronger basis to address that gap. It supports the idea that precision medicine should be integrated into health-system strengthening, including cancer control, early detection, diagnosis, treatment and monitoring.
That matters because precision oncology cannot be delivered through science alone. It needs functioning systems.
WHO now has a mandate to support country readiness
The resolution also gives WHO an important role. WHO is asked to review and map existing guidance relevant to precision medicine, provide technical and normative support to countries, and help Member States strengthen policy, governance, regulation and capacity-building.
One of the most useful proposals is a country maturity model. This would give countries a structured way to assess where they stand, identify priorities, track progress and plan implementation according to their own health-system readiness.
That kind of staged approach is essential. Precision medicine cannot be copied and pasted from one country to another. Health systems differ. Budgets differ. Workforce capacity differs. Data infrastructure differs. Political priorities differ.
WHO is also asked to consider the development of a global strategy on precision medicine, with a possible route towards adoption by the Eighty-second World Health Assembly in 2029. If taken forward, this strategy should not become another high-level document that celebrates innovation without confronting delivery. It should help countries answer harder questions.
Who gets tested? Who pays? Which technologies bring real value? How are patients protected? How are data systems governed? How do countries avoid importing tools that were not designed for their populations? How do we make sure precision medicine strengthens universal health coverage rather than competing with it?
Those are the questions that will determine whether this resolution changes anything.
The real test starts now
The adoption of the resolution is a strong signal. But resolutions do not treat patients. Systems do.
The real test will be whether countries turn the text into action: national strategies, investment plans, diagnostic networks, reimbursement pathways, workforce programmes, ethical data frameworks and measurable access targets.
For Europe, this should also be a wake-up call. The policy pieces are already on the table: health data, health technology assessment, diagnostics, cancer plans, AI regulation, pharmaceutical reform and cross-border cooperation. But these pieces still need to work together in practice. Precision medicine exposes the weakness of fragmented policymaking. It forces health systems to connect science, regulation, data, reimbursement and clinical delivery.
For global health, the message is just as clear. Precision medicine must not become the next frontier that widens the distance between high-income and low-income settings. If planned properly, it can help close gaps. If left to market forces alone, it will deepen them.
The message from Geneva
The World Health Assembly has made precision medicine a global policy issue.
That matters.
The question is no longer whether genomics, diagnostics, AI and data-driven care can transform health. They already can. The question is whether governments are prepared to build the systems needed to make that transformation fair.
Precision medicine should not be a privilege for the few. It should be part of a serious plan for better, more targeted and more equitable care.
The WHA resolution points in that direction. Now policymakers have to do the harder part: fund the diagnostics, build the infrastructure, govern the data, train the workforce, align reimbursement and make sure patients actually benefit.
That is where the future of precision medicine will be decided.
